Neurogene
Dr. Patroneva, M.D., is a highly accomplished neurologist and epileptologist with over 25 years of industry experience in Neuroscience Drug Development and Medical Affairs. Prior to joining Neurogene, Dr. Patroneva worked as Chief Medical Officer at Marinus Pharmaceuticals, overseeing Clinical Development, Regulatory Affairs, Clinical Operations, and Patient Safety for multiple neurology and orphan diseases. Dr. Patroneva also served as Vice-President of the Clinical Development and Medical Affairs departments at Harmony Biosciences, where she established and initiated start-up activities for four neurology orphan indications. Prior to that, Dr. Patroneva served as Vice-President of Global Medical Affairs and Global Head of Multiple Sclerosis and Neurodegenerative Disorders at TEVA Pharmaceuticals, and has held other roles in CNS drug development, leading the full spectrum of clinical development activities from first-in-human trials through product launch and life cycle management. Dr. Patroneva received her medical degree at the Medical Academy of Sofia, Bulgaria. She holds board certification in neurology and early work in academia, including serving as Head of the EEG Lab at the Military Medical Academy of Sofia, Bulgaria, and as Assistant Professor of Neurophysiology at the Alexandrov Medical Hospital in Sofia. Dr. Patroneva also has an MBA in Health Management from Assen Zlatarov University in Burgas, Bulgaria.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.